Chemotherapy News and Research

Latest Chemotherapy News and Research

CytRx granted European patent for tumor-targeting linker platform technology

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that the European Patent Office (EPO) has issued a patent covering the Company's tumor-targeting linker platform technology and pharmaceutical compositions.

2 Jul 2012

Blocking AXL protein may prevent resistance to lung cancer drug

People with lung cancer who are treated with the drug Tarceva face a daunting uncertainty: although their tumors may initially shrink, it's not a question of whether their cancer will return—it's a question of when. And for far too many, it happens far too soon.

2 Jul 2012

Clinical results for Teva's biologic oncology candidates presented at MASCC/ISOO 2012

Teva Pharmaceutical Industries Ltd. announced today the presentation of clinical results for its biologic oncology candidates, lipegfilgrastim and balugrastim, at the Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) 2012 International Symposium on Supportive Care in Cancer being held in New York June 28-30.

2 Jul 2012

New volumetric functional MRI scan figures out beneficiaries of chemotherapy in liver cancer patients

Studies on some 55 U.S. men and women with potentially deadly liver or pancreatic cancers show that specialized MRI scans can tell within a month whether highly toxic chemotherapy is working and killing tumor cells long before tumors actually shrink - or fail to shrink.

2 Jul 2012

Genetic mutation that creates Ewing's sarcoma leads to high levels of protein EYA3

Ewing's sarcoma is a bone cancer commonly diagnosed in about 250 U.S. teenagers per year. If early chemotherapy is effective, improvement can be durable. But for children and teens who respond poorly to a first attempt at chemotherapy or if the disease spreads, long-term survival can be less than 10 percent.

30 Jun 2012

A.P. Pharma announces additional data from APF530 Phase 3 study on CINV

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced additional data from the Company's Phase 3 study of APF530 for the prevention of chemotherapy-induced nausea and vomiting (CINV).

29 Jun 2012

Results from Access’ MuGard Phase 4 trial on oral mucositis

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company developing treatments in areas of oncology and oncology supportive care, announced that Dr. Ron R. Allison of Carolina Radiation Medicine, Greenville, NC, presented results from its ongoing MuGard Phase 4 clinical trial in oral mucositis (OM) at the Multinational Association of Supportive Care in Cancer (MASCC) Conference in New York City.

29 Jun 2012

LUMC oncologist presents survival data for brentuximab vedotin at 17th EHA Congress

A new cancer drug with remarkably few side effects is dramatically improving survival in Hodgkin lymphoma patients who fail other treatments and are nearly out of options.

28 Jun 2012

Pediatric Hodgkin lymphoma can be treated without radiation and intensive chemotherapy

A multicenter trial showed that nearly half of young patients with early-stage Hodgkin lymphoma can be cured without undergoing either irradiation or intensive chemotherapy that would leave them at risk for second cancers, infertility, heart and other problems later.

28 Jun 2012

Jin Shin Jyutsu improves side effects of cancer treatment

A new study by the University of Kentucky Markey Cancer Center shows that patients reported significant improvement in side effects of cancer treatment following just one Jin Shin Jyutsu session. Jin Shin Jyutsu is an ancient form of touch therapy similar to acupuncture in philosophy.

27 Jun 2012

New approach improves survival in patients with inoperable complex pancreatic adenocarcinoma

Investigators at the University of Texas MD Anderson Cancer Center, Houston, have reported on a new approach to treating previously inoperable complex pancreatic adenocarcinoma that has significantly increased long-term survival for some patients.

27 Jun 2012

Astellas submits enzalutamide MAA with EMA for treatment of CRPC

Today, Astellas Pharma Inc. announces the submission of a European marketing authorisation application to the European Medicines Agency (EMA) for enzalutamide for the treatment of men with metastatic castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.

27 Jun 2012

MRI scans determine whether chemotherapy is working long before tumors shrink

26 Jun 2012

New drug better than chemotherapy for skin cancer patients

A new drug, dabrafenib, shows improvements over chemotherapy for patients suffering from a form of advanced skin cancer, according to the results of a Phase III study (“BREAK-3” trial) published Online First in the Lancet.

26 Jun 2012

Cancer survivors benefit from healthy lifestyle

Australia’s first community-based Cancer Survivors Centre, which is based at the University of New South Wales, has joined the Dry July campaign in a bid to pinpoint the vital role a healthy lifestyle plays in fending off cancer and the after-effects of the disease.

26 Jun 2012

Experimental medication increases muscle strength in cancer patients with low testosterone levels

An experimental medication safely increases muscle strength and physical functioning among cancer patients with low testosterone levels, a new drug study finds. The results will be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston.

26 Jun 2012

LLUMC suggests check list with six key attributes for successful proton therapy treatment

When a newly diagnosed cancer patient is considering treatment options, proton therapy might not be the first course that comes to mind. Yet over the past two decades proton therapy has continued to evolve as a viable alternative to chemotherapy and a less-invasive procedure than radiation or surgery, so much so that proton therapy is now considered the preferred course of treatment for many doctors and patients in the fight against cancer.

26 Jun 2012

Amgen launches Chemotherapy: Myths or Facts campaign for cancer patients

Amgen today launched Chemotherapy: Myths or Facts, an awareness campaign for cancer patients and their caregivers featuring Emmy-nominated actress and breast cancer survivor Maura Tierney.

26 Jun 2012

CytRx achieves key milestone in advancing tamibarotene Phase 2b trial for NSCLC

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the recommendation by the Data Safety Monitoring Board (DSMB) to continue with the global Phase 2b clinical trial with tamibarotene in combination with chemotherapeutical agents as a first-line treatment for patients with advanced non-small-cell lung cancer.

26 Jun 2012

New analysis finds increase in per-patient operating costs in PCMHs

The patient-centered medical home (PCMH) is a concept at the heart of many health care reform models that aim to both improve the quality of care and reduce wasteful spending. But a new analysis of federally qualified health centers finds that clinics with higher scores as medical homes also had higher per-patient operating costs.

25 Jun 2012

Chemotherapy News and Research

Latest Chemotherapy News and Research

CytRx granted European patent for tumor-targeting linker platform technology

Blocking AXL protein may prevent resistance to lung cancer drug

Clinical results for Teva's biologic oncology candidates presented at MASCC/ISOO 2012

New volumetric functional MRI scan figures out beneficiaries of chemotherapy in liver cancer patients

Genetic mutation that creates Ewing's sarcoma leads to high levels of protein EYA3

A.P. Pharma announces additional data from APF530 Phase 3 study on CINV

Results from Access’ MuGard Phase 4 trial on oral mucositis

LUMC oncologist presents survival data for brentuximab vedotin at 17th EHA Congress

Pediatric Hodgkin lymphoma can be treated without radiation and intensive chemotherapy

Jin Shin Jyutsu improves side effects of cancer treatment

New approach improves survival in patients with inoperable complex pancreatic adenocarcinoma

Astellas submits enzalutamide MAA with EMA for treatment of CRPC

MRI scans determine whether chemotherapy is working long before tumors shrink

New drug better than chemotherapy for skin cancer patients

Cancer survivors benefit from healthy lifestyle

Experimental medication increases muscle strength in cancer patients with low testosterone levels

LLUMC suggests check list with six key attributes for successful proton therapy treatment

Amgen launches Chemotherapy: Myths or Facts campaign for cancer patients

CytRx achieves key milestone in advancing tamibarotene Phase 2b trial for NSCLC

New analysis finds increase in per-patient operating costs in PCMHs

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in